Fax: (011) 82 2 792 9878
The prevalence and assessment of ErbB2-positive breast cancer in Asia
A literature survey
Article first published online: 16 AUG 2010
Copyright © 2010 American Cancer Society
Volume 116, Issue 23, pages 5348–5357, 1 December 2010
How to Cite
Tan, Y. O., Han, S., Lu, Y.-S., Yip, C.-H., Sunpaweravong, P., Jeong, J., Caguioa, P. B., Aggarwal, S., Yeoh, E. M. and Moon, H. (2010), The prevalence and assessment of ErbB2-positive breast cancer in Asia. Cancer, 116: 5348–5357. doi: 10.1002/cncr.25476
- Issue published online: 23 NOV 2010
- Article first published online: 16 AUG 2010
- Manuscript Accepted: 13 MAY 2010
- Manuscript Revised: 10 MAY 2010
- Manuscript Received: 10 MAR 2010
- Unknown funding agency
- breast neoplasms;
- fluorescence in situ hybridization;
- erbB-2 receptor
Overexpression of the epidermal growth factor receptor-related gene ErbB2 occurs in 18% to 25% of patients with breast cancer in Western countries and is associated with a poor prognosis. The prevalence of ErbB2-positive tumors in Asia is unclear, partly because data are limited. The objective of this review was to summarize the reported prevalence of ErbB2-positive tumors from a large sample of Asian patients and to examine ErbB2 assessment methods in Asia. From searches of MEDLINE, local language journals, and local and international conference proceedings as well as locoregional breast cancer experts' recommendations, the authors selected up to 5 studies each from India, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand that reported ErbB2 results based on assessment with immunohistochemistry (IHC) and/or fluorescence in situ hybridization (FISH). The reported prevalence of ErbB2-positive tumors in 22 studies on 24,671 patients, of whom 14,398 patients were assessed for ErbB2 status, varied widely (range, 6%-65%) as did the assessment methods used. Most studies (n = 21) used IHC to assess ErbB2 status, but definitions for positivity varied. When robust assessment methods were used, the median prevalence was 19% based on strong IHC staining (IHC3+; n = 9812 patients) and 25% based on FISH (n = 681 patients). Data on the prevalence of ErbB2-positive breast cancer in Asia are limited. The current survey indicated that the prevalence in Asia may be similar to that in Western countries; thus, up to 1 in 4 Asian patients with breast cancer potentially could benefit from ErbB2-targeted treatment. A standard, reliable ErbB2 assessment method available to patients across Asia is urgently required. Cancer 2010. © 2010 American Cancer Society.
Although the incidence of breast cancer in some Western countries has fallen recently, its incidence still is increasing in Asia.1, 2 Furthermore, the survival rate among patients with breast cancer in Asia is approximately half that of patients in Western countries.2, 3 These observations are driving interest in gaining a better understanding of breast cancer in Asia.
Studies from Western countries indicate that breast cancer survival is low in patients with tumors that over express the human epidermal growth factor receptor-related gene ErbB2 (c-ErbB2, HER2, or neu).4, 5 Tumors that over express ErbB2 are more likely to recur4, 5 and are relatively resistant to many treatments.4 Two recently developed treatments that specifically target ErbB2, trastuzumab and lapatinib, are effective either alone or with chemotherapy in reducing tumor recurrence and mortality in patients with ErbB2-positive breast cancer.6
Given the increasing incidence of breast cancer in Asia and the clinical consequences of ErbB2-positive breast cancer, insight into the prevalence of ErbB2-positive tumors in Asia is important. Recently, 2 large studies of breast cancer registry data in the United States reported that women of Asian descent were more likely to have ErbB2-positive tumors than Caucasian women,7, 8 suggesting possible racial differences. Whether the prevalence of ErbB2-positive breast cancer differs between Asian and Western countries requires clarification. A higher prevalence of ErbB2-positivity may be 1 of several factors contributing to the lower survival rate of Asian breast cancer patients.
Because ErbB2 status is assessed by different methods (by immunohistochemistry [IHC] or, less commonly, by fluorescence in situ hybridization [FISH]9), it is also important to know how ErbB2 is assessed within different Asian countries. The accurate estimation of the prevalence of ErbB2-positive tumors in Asia has been hindered by variability in both the availability of assessment methods and the definition of ErbB2 positivity. In addition, data on ErbB2 positivity in Asia are limited in the literature that can be searched electronically (eg, in the MEDLINE database).
To gain insight into the prevalence and assessment of ErbB2-positive breast cancer in Asia through a literature survey, we formed the Early Breast Cancer Working Group (EBCWG). Because we anticipated that it would be a challenge to find data on ErbB2 prevalence in Asia, we also engaged with our peers who were familiar with relevant research in our countries. The objectives of our literature survey were to summarize the reported prevalence of ErbB2-positive breast cancer in 7 Asian countries and to examine the ErbB2 assessment methods used in these countries.
MATERIALS AND METHODS
Literature Search Strategy
After the initial EBCWG meeting, we conducted separate literature searches for our respective countries (India, Korea, Malaysia, the Philippines, Singapore, Taiwan, and Thailand). We obtained relevant literature from searches of the MEDLINE database using PubMed (2000 to September 2008) with the search terms (ErbB2 OR HER2 OR ErbB-2 OR HER-2) AND “breast cancer” AND (country of interest). We also searched, either electronically or by hand, local language journals and the proceedings of local and international oncology conferences, and we consulted with our professional networks for access to results from recent studies. Because the availability and quality of ErbB2 assessment in Asian clinics increased after the approval of trastuzumab in 2000, we limited our searches to studies that were published during or after 2000.
Study Selection Criteria
We selected studies that reported the results of ErbB2 assessment by IHC, FISH, or both for further review. To focus on clinical ErbB2 assessment in our countries, we excluded studies of Asian patients who were living in Western countries and studies that reported serum, messenger RNA, or cell line ErbB2 data. For each country, we selected up to 5 studies for detailed review. Preference was given to studies that had large sample sizes, multicenter studies, and studies that were published in higher impact factor journals.
The EBCWG met again to analyze data from the selected studies. We divided the ErbB2 prevalence data from the studies into 3 categories based on the testing and grading methods used for assessment: 1) IHC combined or not specified, ie, IHC with intermediate (IHC2+) and strong (IHC3+) staining combined or IHC with no grading method specified; 2) IHC3+ only; and 3) FISH. Then, we calculated the median and mean (±standard deviation) prevalence of ErbB2-positive tumors in each category.
We hypothesized that lower income countries may report higher ErbB2+ prevalence rates because of the limited availability of robust, but expensive, assay methods (eg, FISH). We used a 2-sample t test (assuming unequal variances) to compare differences between low/middle-income countries and high-income countries in the reported ErbB2+ prevalence rates assessed with IHC2+/IHC3+ combined or not specified, IHC3+ only, or FISH. Countries were classified as low, middle, or high income based on the 2007 World Bank income classification (available at: http://data.worldbank.org/about/country-classifications/a-short-history accessed July 23, 2010).
Summary of Selected Literature
We selected 22 studies (see Table 1), including 17 publications10-26 and 5 conference abstracts,27-31 for further review. For Malaysia30, 31 and the Philippines,29 only conference abstracts met our selection criteria.
|Study and Design||Sampling||Patients (%)|
|No.||Setting||Dates||Age||Stage or Gradea|
|Bhamrah 200827; observational||210||All India Institute of Medical Sciences||NR||NR||NR|
|Meenakshi 200317; prospective, observational||127||Cancer Institute||NR||NR||NR|
|Kim 200614; retrospective, observational||776||Asan Medical Center||1993-1998||Mean, 47.4 y; range, 24-88 y||Stage: I, 182 (23.5); II, 336 (47.2); III, 225 (29); IV, 3 (0.4)|
|Korean Breast Cancer Society, 200624; retrospective, observational||Total, 9668; ErbB2- tested, 4318||Medical schools, 39; hospitals, 27; private clinics, 7||2004||Age known: 8376; median, 47 y; ≤29 y, 157 (1.9); 30-39 y, 1409 (16.8); 40-49 y, 3452 (41.2); 50-59 y, 1987 (23.7); 60-69 y, 1017 (12.1); ≥70 y, 354 (4.2)||Total assessed, 5301 (100); Stage: 0, 508 (9.6); I, 1889 (35.6); II, 2062 (38.9); III, 772 (14.6); IV, 70 (1.3)|
|Park 200319; prospective, observational||188||University Sanggye Paik Hospital||NR||NR||Histologic gradeb: 1, 22 (11.7); 2. 83 (44.1); 3. 73 (38.8); unknown: 10 (5.3)|
|Park & Han 200418; observational||Samples in TMA, 132-261||Inje University Sanggye Paik Hospital||NR||NR||NR|
|Shin 200622; retrospective, observational||Total, 4063; ErbB2- tested, 2196||Seoul National Universiti Hospital||1981-2002||Median, 46 y; ≤29 y, 163 (4); 30-39 y, 983 (24.2); 40-49 y, 1572 (38.7); 50-59 y, 921 (22.7); 60-69 y, 334 (8.2); ≥70 y, 79 (1.9); unknown, 16 (0.4)c||Total assessed, 3761 (100); Stage: 0, 175 (4.7); I, 1042 (27.7); II, 1652 (43.9); III, 726 (19.3); IV, 166 (4.4)|
|Shahrun 200830; retrospective, observational||300||International Islamic University Malaysia; Universiti Kebangsaan Malaysia||2003-2007||NR||NR|
|Tan &Yip 200831; prospective, observational||393||University Malaya Medical Center||2007||<40 y (12); ≥40 y (88)||Stage: 0, 11 (2.7); I, 98 (24.8); II, 189 (48.2); III, 61 (15.5); IV, 34 (8.7)|
|Fernandopulle 200612; retrospective, observational||112||Singapore General Hospital||1993-2004||All, ≤35 y; mean, 29.1 y; median, 30 y; range, 19-35 y||Histologic graded: 1, 7 (6.3); 2, 24 (21.4); 3, 54 (48.2); unknown, 27 (24.1)|
|Selvarajan 200620; retrospective, observational||184||Singapore General Hospital||1998-2002||NR||NR|
|Selvarajan 200621; retrospective, observational||321||Singapore General Hospital||1998-2002||≤50 y; 134 (41.7); >50 y, 181 (56.4); unknown, 6 (1.9)||Stage: I, 68 (21.2); II, 102 (61.8); III, 23 (13.9); IV, 5 (3)|
|Tan 200823; retrospective, observational||165||National Cancer Centre Tissue Repository||2000-2004||Mean±SD, 56±12 y; range, 30-79 y; ≤54 y, 82 (49.7); >54 y, 83 (50.3)||Stage: I, 36 (21.8); II, 192 (59.8); III, 28 (8.7); IV, 7 (2.2); unknown, 26 (8.1)e|
|Zhang 200326; retrospective, observational||97||National University Hospital||NR||NR||Histologic gradef: 1, 9 (9.3); 2, 34 (35.1); 3, 44 (45.4); unknown, 10 (10.3)|
|Chen 200811; open label, phase 2 trial||63||Chang Gung Memorial Hospital||2002-2005||Median, 46 y; range, 29-69 y||Tumor classification: T2, 25 (39.7); T3, 32 (50.8); T4, 6 (9.5)|
|Huang 200813; prospective pilot trial||192||Kaohsiung Medical University Hospital||2003-2005||Median±SD, 48.9±9.6 y; <50 y, 112 (58.3); ≥50 y, 80 (41.7)||Stage: II, 160 (83.3); III, 32 (16.7)|
|Lin 200716; Phase 2 randomized controlled trial||101||Chang Gung Memorial Hospital||2000-2002||Median, 48 y; range, 25-70 y||All stage IV|
|Lin 200915; prospective, observational||1028||National Taiwan University Hospital||2004-2006||Median, 50 y; range, 23-88 y||Stage: I, 316 (30.7); II, 417 (45.8); III, 176 (17.1); IV, 52 (5.1); unknown, 13 (1.3)|
|Tsai 200125; retrospective, observational||167||Kaohsiung Medical University Hospital||1990-1999||Mean age: Familial, 47.8 y, n=56; nonfamilial, 50.1 y, n=111||Histologic gradeg: 1, 13 (7.8); 2, 51 (30.5); 3, 63 (37.7); unknown, 40 (24)|
|Chearskul 200110; retrospective, observational||506||Siriraj Hospital||1992-2000||Mean age, 50.8 y; range, 24-89 y; ≤50 y, 246 (48.6); >50 y, 255 (50.4); unknown, 5 (1)||I, 50 (9.9); II, 366 (72.3); III, 60 (11.9); IV, 5 (1); unknown, 25 (4.9)|
|Moohamad 200828; retrospective, observational||442||Phramongkutklao Hospital||2003-2006||NR||NR|
|Sanchez 200729; retrospective, observational||Total, 5307; ErbB2- tested, 2333||St. Luke's Medical Center||1994-2004||NR||NR|
Patients Assessed for ErbB2
Our selected studies included 24,671 patients, including 14,398 patients (58.4%) who were assessed for ErbB2 (Table 1). The number of patients in each study ranged from 63 patients11 to 9668 patients,24 and the number assessed for ErbB2 ranged from 63 patients11 to 4319 patients.24 The age of patients varied widely (range, 19-89 years) among those studies in which it was reported; however, most patients were in their 40s or 50s. Most patients (10,203 of 13,171 patients; 77.5%) for whom cancer stage was reported had early stage breast cancer (stage 0, n = 694 [5.3%]; stage I, n = 3732 [28.3%]; stage II, n = 5777 [43.9%]).
Prevalence of ErbB2-Positive Breast Cancer
The prevalence of ErbB2-positive breast cancer in Asia was influenced by the testing method and grading criteria used (Tables 2 and 3). Generally, prevalence results were lowest with IHC when positivity was defined as IHC3+, intermediate with FISH, and highest with IHC when positivity was defined as IHC2+ and IHC3+ combined or when positivity was not defined. When the results obtained using any of the assessment methods were examined, the prevalence of ErbB2-positive breast cancer varied widely (range, 6%-65%). When results were limited to those obtained with the more robust methods (IHC3+, FISH), the median prevalence was 19% and 25%, respectively (Fig. 1). Even with this narrower focus, these results were obtained from 10,076 patients in 5 Asian countries (India, Korea, Singapore, Taiwan, and the Philippines). The least variable results were obtained with the less common assessment method, FISH (Table 3).
|Study||ErbB2 Assessment||Percentage of Patients (No./Total No.)|
|IHC2+ and IHC3+a||IHC3+b||FISH|
|Bhamrah 200827||IHC: antibody, NR||28.6 (60/210)cd||NR||NR|
|Meenakshi 200317||IHC2+, IHC3+: antibody, in-house monoclonal (CIBCgp185)||25.2 (32/127)||15.7 (20/127)||NR|
|Kim 200614||IHC3+: ≥10% cells positive; antibody, Dako (Glostrup, Denmark)||NR||25 (194/776)||NR|
|Korean Breast Cancer Society 200624||IHC2+, IHC3+; antibody: NR||36.9 (1594/4319)||19.8 (854/4319)||NR|
|Park 200319||FISH: signal ≥2-fold centromere region of chromosome 17; CISH: gene copy >4||NR||NR||24.5 (46/188)|
|Park & Han, 200418||IHC2+, IHC3+: antibodies, HercepTest (Dako), rabbit anti-c-ErbB2 (Zymed, South San Francisco, Calif), mouse anti-c-ErbB2 (Zymed); FISH: criteria not reported in English||17.9-22.7 (40/188)e||6.1-14.4 (21/188)e||24-28 (73/261)ef|
|Shin 200622||IHC2+, IHC3+: antibody, NR||51.5 (1131/2196)||NR||NR|
|Shahrun 200830||NR||44.4 (133/300)cg||NR||NR|
|Tan & Yip, 200831||IHC2+, IHC3+: antibody, Dako||60.6 (238/393)c||34.5 (136/393)c||NR|
|Fernandopulle 200612||IHC2+, IHC3+: antibody, rabbit polyclonal (A0485; Dako)||29.6 (16/54)||NR||NR|
|Selvarajan 200620||IHC2+, IHC3+: antibody, rabbit polyclonal, Dako (A0485; Dako); performed on standard sections and TMA||21.2 (39/184)||12.5 (23/184)h||NR|
|Selvarajan 200621||IHC2+, IHC3+: antibody, rabbit polyclonal (Dako)||34.3 (110/321)||NR||NR|
|Tan 200823||IHC2+, IHC3+: antibody: SP3, Lab Vision (Thermo Fisher Scientific, Waltham, Mass); FISH: signal ≥2.2-fold centromere region of chromosome 17 (PathVysion, Des Plaines, Ill)||19 (27/142)||11.3 (16/142)||37.9 (55/145)|
|Zhang 200326||IHC2+, IHC3+: antibody, HercepTest; FISH: signal ≥2-fold centromere region of chromosome 17 (PathVysion)||25 (23/92)||15.2 (14/92)||23 (20/87)|
|Chen 200811||IHC3+: antibody, HercepTest||NR||19 (12/63)||NR|
|Huang 200813||NR||64.6 (124/192)g||NR||NR|
|Lin 200716||NR||27.7 (28/101)g||NR||NR|
|Lin 200915||IHC3+: antibody, polyclonal (Dako); IHC2+: confirmation by FISH (signal ≥2-fold centromere region of chromosome 17; PathVysion)||NR||20.5 (211/1028)i||NR|
|Tsai 200125||IHC3+: antibody, HercepTest||NR||41.3 (69/167)||NR|
|Chearskul 200110||IHC2+: antibody, rabbit polyclonal (Dako)||32.2 (163/506)||NR||NR|
|Moohamad 200828||IHC: antibody, NR||17.9 (79/442)g||NR||NR|
|Sanchez 200729||IHC3+: antibody, NR||NR||20 (466/2333)||NR|
|Characteristic||ErbB2 Assessment Method|
|IHC2+ and 3+a||IHC3+b||FISH|
|Studies using method, no.c||16||12||4|
|ErbB2-positive patients, no./total no.c||3837/9767||2036/9812||194/681|
|ErbB2-positive prevalence, %|
The mean prevalence of ErbB2-positive tumors was similar to the median prevalence for all 3 assessment methods (Table 3). Omitting the maximum and minimum prevalence values did not change the mean markedly (IHC2+/IHC3+ combined or not specified = 32.6% vs an actual rate of 33.7%; IHC3+ only = 19.4% vs an actual rate of 20.4%).
When prevalence data from high-income (Korea, Singapore, and Taiwan) and low or middle-income (India, Malaysia, Thailand, and the Philippines) countries were compared, there was no significant difference (P = .82) in the mean prevalence when positivity was defined as IHC2+/IHC3+ or when the definition was not specified. Similarly, there was no significant difference (P = .59) in the mean prevalence when positivity was defined as IHC3+. The similarity in prevalence results between high-income and low or middle-income countries also was apparent from a comparison of the median values for IHC (Fig. 1). No comparison could be made for studies using FISH, because none of the studies from low or middle-income countries used this method. Among the countries in our survey, only high-income countries (ie, Korea, Singapore, and Taiwan) routinely tested for ErbB2 status and subsidized the cost of trastuzumab for eligible patients (Table 4).
|Variable||High-Income Countries||Low/Middle-Income Countries|
ErbB2 Assessment Methods
The most common ErbB2 assessment method was IHC, which was used in 21 of 22 studies (95.5%). Although 12 studies provided the name and/or supplier of the antibody used, 7 studies (including the 5 conference abstracts) did not specify either. The most commonly used antibodies were from Dako (Glostrup, Denmark), including 4 studies that used the HercepTest (Dako), 2 studies that used the A0485 rabbit polyclonal antibody, and 4 studies that used unspecified Dako antibodies. Only 4 studies18, 19, 26, 31 from 2 countries (Korea and Singapore) used FISH to assess ErbB2, whereas 1 study from Taiwan15 used FISH to confirm ErbB2 positivity in tumors with IHC2+ staining.
On the basis of the ErbB2 assessment results from 14,398 patients in 7 Asian countries, our literature survey indicated that the reported prevalence of ErbB2-positive breast cancer has varied from 6% to 65%. However, when ErbB2 was assessed robustly using IHC3+ or FISH, the median prevalence, based on the results from 10,076 Asian patients in 5 countries, was 19% with IHC3+ and 25% with FISH. These prevalence results are similar to those in Western countries.4, 5 Because ErbB2 status is predictive for both prognosis and therapeutic response, knowledge of a patient's ErbB2 status could help physicians identify the most appropriate treatment. Our survey indicates that up to 1 in 4 Asian patients with breast cancer potentially could benefit from ErbB2-targeted treatment. In addition, the variability in ErbB2 assessment methods evident from our survey highlights the need for Asian countries to use a standard, reliable method to assess ErbB2. Enhanced ErbB2 assessment methods would enable us to further refine our understanding of the prevalence of ErbB2-positive breast cancer in Asia.
To the best of our knowledge, this is the first survey of ErbB2-positivity results obtained from a large sample of patients to indicate that the prevalence of ErbB2-positive breast cancer in Asia is similar to that in Western countries (range, 18%-25%).4, 5 Notably, this finding is based on Asian data that were obtained using the more robust assessment methods, IHC3+ and FISH.32, 33 Because the prevalence of ErbB2-positive tumors is not apparently higher in Asia, alternative reasons for the low breast cancer survival rate should be explored. Possible reasons include advanced stage at diagnosis3, 34; younger patients (aged <50 years; associated with more aggressive tumors)3, 35; higher prevalence of estrogen or progesterone receptor-negative tumors, which are less responsive to endocrine therapies3, 36; and the cost and availability of treatments, including those that target ErbB2.3, 34
In our survey, we observed considerable variability in ErbB2 assessment methods. The most common method was IHC; however, many factors contribute to variability in IHC results, including the antibody used4, 9 and the grading criteria.9 The relatively small size of many Asian laboratories also may have contributed to the variability we observed. Indeed, the concordance in IHC results between small, local laboratories and high-throughput, central laboratories can be unacceptably low.9
We also observed great variability in how IHC results were reported. Many studies reported both IHC2+ and IHC3+ staining separately. However, although some categorized both IHC2+ and IHC3+ staining as positive,12, 17, 18, 20, 21 others categorized only IHC3+ staining as positive.11, 14, 25, 29 Recent guidelines that were published jointly by the American Society for Clinical Oncology and the College of American Pathologists (ASCO/CAP) recommend reporting IHC2+ and IHC3+ staining separately and confirming the ErbB2 status of IHC2+ tumors by FISH.9 These recommendations are based on the poor concordance between IHC2+ staining and gene amplification by FISH.4, 9, 32, 33 Among the studies in our survey, only 5 used FISH to determine or confirm ErbB2 status.15, 18, 19, 26, 31 Not surprisingly, these studies were conducted in Korea, Singapore, and Taiwan, countries that are able to fund this more expensive method.
Despite the apparent similarity in the prevalence of ErbB2-positive breast cancer in Asian and Western countries, many Asian patients will not have the same opportunity as Western patients to receive ErbB2-targeted treatment. ErbB2-positive tumors respond well to ErbB2-targeted treatments,6 but these treatments are expensive and, thus, may not be available to many Asian patients (Table 4). Without subsidies, many Asian patients with ErbB2-positive breast cancer may not be able to afford ErbB2-targeted treatments, which in turn, may reduce the incentive for ErbB2 assessment. Individual countries need to weigh the costs of ErbB2 assessment and treatment with the potential benefit for patients. Because our survey suggests that the prevalence of ErbB2-positive tumors is not related to country income level, at least there is no epidemiologic justification for restricting ErbB2 assessment and treatment in lower income countries.
Worldwide standardization of ErbB2 assessment is an important goal not only for obtaining unbiased data on the prevalence of ErbB2-positive breast cancer but also to ensure that patients receive the most appropriate treatment. Ideally, a standardized assessment method would adhere to the ASCO/CAP guidelines.9 However, we must emphasize that the stringent ASCO/CAP recommendations are not practical in many lower income countries.9 We believe that greater standardization of ErbB2 assessment is particularly needed in the low or middle-income countries that were included in our study (India, Malaysia, Thailand, and the Philippines)(Table 4). The Breast Health Global Initiative recognizes that the costs of ErbB2 assessment, especially FISH, and ErbB2-targeted therapies are “prohibitively expensive” in countries with limited resources.37 Because ErbB2 assessment is not routine in many Asian countries, it would be beneficial, if not prudent, to provide pathologists with a standardized protocol and regular validation testing. Given the impact of pathologist and laboratory experience on ErbB2 results, smaller Asian countries also might consider establishing a central laboratory for national ErbB2 assessment.
Our survey has strengths and limitations. We believe that our conclusions regarding the prevalence of ErbB2-positive breast cancer and ErbB2 assessment methods in Asia are strengthened by the use of data from 22 studies involving more than 14,000 patients in 7 Asian countries that vary in ethnicity, size, and economic status. In addition, as experts in our respective countries, we were able to include data from local language journals and conferences, which are not readily available from the MEDLINE database. However, we recognize that our survey does have limitations. We did not perform a comprehensive, systematic literature review; rather, we chose to limit the number of studies we included from each country to avoid over-representation of larger, wealthier countries with more available data. For some countries in our survey, the only available studies that met our criteria were published as conference abstracts. We chose to include these studies, despite their preliminary nature, to examine the current state of ErbB2 assessment and prevalence in these countries. Although data for Malaysia were limited at the time of our survey, the prevalence of ErbB2 positivity reported in a recent article is consistent with the prevalence we obtained.38 Also, although our survey included data from 7 countries, we did not include data from all Asian countries. Notably, we did not include data from Japan or China. However, our prevalence results are consistent with those reported in recent studies from Japan;39, 40 (range, 11%-27%) and China41(20%). Finally, any literature survey is retrospective in nature and, as we observed, is subject to data heterogeneity. Among other factors, referral bias may have affected the prevalence reported by some researchers, particularly those from specialist centers. Whether the data in our selected studies are representative of the wider population of breast cancer patients in these countries cannot be determined until further studies are conducted. Nevertheless, as regional breast cancer experts, we believe the available data, although limited, are consistent with our clinical experience.
In summary, data on the prevalence of ErbB2-positive breast cancer in Asia are limited. Nevertheless, our survey, based on data from 14,398 patients in 7 Asian countries, indicates that the reported prevalence of ErbB2-positive breast cancer has varied widely from 6% to 65%. However, when ErbB2 status was assessed robustly, the median prevalence, based on data from 10,076 patients in 5 Asian countries, was 19% (IHC3+) or 25% (FISH), similar to that in the West. Because ErbB2 status is predictive of both prognosis and responsiveness to targeted therapies, Asian countries should work toward standardization of ErbB2 assessment.
CONFLICT OF INTEREST DISCLOSURES
This study was sponsored by Glaxo SmithKline Asia Pacific (Singapore). Dr. Aggarwal has acted as a consultant for Glaxo SmithKline, AstraZeneca, Dabur, and Roche, and has received honoraria from GlaxoSmithKline, Bristol-Myers Squibb, AstraZeneca, and Merck. Drs. Yip and Sunpaweravong have acted as consultants for GlaxoSmithKline. Drs. Yeoh and Moon are employees of GlaxoSmithKline Asia Pacific. The authors acknowledge the independent medical writing assistance provided by ProScribe Medical Communications (www.proscribe.com.au [accessed July 23, 2010]), funded from an unrestricted financial grant from GlaxoSmithKline Asia Pacific. ProScribe's services complied with international guidelines for Good Publication Practice.
- 8Breast cancer subtypes as defined by the estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. Breast J. 2009; 5: 593-602., , ,
- 22Postoperative survival and prognostic factors in breast cancer: a single center analysis of 4,063 cases. J Breast Cancer. 2006; 9: 55-60., , , et al.
- 24The Korean Breast Cancer Society. Nationwide Korean breast cancer data of 2004 using breast cancer registration program. J Breast Cancer. 2006; 9: 151-161.
- 28Are there any differences in the characteristics of breast cancer with regards to its HER-2/NEU status? Paper presented at: 33rd Annual Scientific Meeting of the Royal College of Surgeons of Thailand; July 17-20, 2008; Pattaya, Thailand., , , ,
- 29HER-2/neu overexpression among Filipino patients with breast cancer: a 10 year review. Paper presented at: 10th International Conference on Primary Therapy of Early Breast Cancer; March 14-17, 2008; St. Gallen, Switzerland., , , et al.
- 30Breast cancer subtypes and its correlation: a retrospective single centre study. Paper presented at: 11th Congress of the Asian Association of Endocrine Surgeons and Annual Scientific Meeting of the College of Surgeons; March 20-22, 2008; Sabah, Malaysia., , ,
- 31Association between tumour characteristics and HER2/neu by immuno-histochemistry in 393 women with breast cancer. Paper presented at: 11th Congress of the Asian Association of Endocrine Surgeons and Annual Scientific Meeting of the College of Surgeons; March 20-22, 2008; Sabah, Malaysia.,
- 32HER2 testing in patients with breast cancer: poor correlation between weak positivity by immunohistochemistry and gene amplification by fluorescence in situ hybridization. Mayo Clin Proc. 2002; 77-154. 148-154., , , et al.